Kiniksa Pharmaceuticals International (KNSA) Cost of Revenue (2021 - 2026)

Kiniksa Pharmaceuticals International (KNSA) has reported Cost of Revenue for 6 consecutive years, with $23.6 million the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cost of Revenue rose 26.71% year-over-year to $23.6 million; the trailing twelve-month figure through Jun 2026 stood at $85.6 million (up 14.9% YoY), and the FY2025 full-year result was $77.7 million, up 27.52% from the prior year.
• Cost of Revenue climbed to $23.6 million in Q2 2026 per KNSA's latest filing, from $20.8 million in the prior quarter.
• Across five years, Cost of Revenue topped out at $23.6 million in Q2 2026 and bottomed at $4.2 million in Q1 2022.
• Historically, Cost of Revenue has averaged $13.3 million across 5 years, with a median of $11.5 million in 2024.
• The sharpest annual moves came in 2022 and 2025: Cost of Revenue soared 150.7% in 2022, then grew 0.74% in 2025.
• Over 5 years, Cost of Revenue stood at $6.7 million in 2022, then jumped by 42.83% to $9.6 million in 2023, then soared by 86.73% to $17.9 million in 2024, then rose by 17.04% to $20.9 million in 2025, then grew by 12.54% to $23.6 million in 2026.
• According to Business Quant data, Cost of Revenue over the past three periods registered $23.6 million, $20.8 million, and $20.9 million for Q2 2026, Q1 2026, and Q4 2025 respectively.